Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | GFER | P55789 | 1/20 | 0.57 |
| ▸ | ATP4A | P20648 | 17/20 | 0.54 |
| ▸ | ATP4B | P51164 | 17/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6989280 | 0.98 | MAPT (0.56) | MAPTNPC1RAB9AGFERATP4A | |
| Bromide SCHEMBL826907 | 0.72 | MAPT (0.97) | MAPTNPC1RAB9AGFERATP4A | |
| SCHEMBL5879530 | 0.72 | CYP1A2 (0.50) | MAPTNPC1RAB9AGFERATP4A | |
| SCHEMBL2359189 | 0.72 | RAB9A (0.46) | NPC1RAB9AATP4AATP4B | |
| SCHEMBL15109249 | 0.71 | — | — | |
| Zaltidine SCHEMBL4606700 | 0.71 | ATP4A (0.63) | MAPTNPC1RAB9AGFERATP4A | |
| SCHEMBL22296554 | 0.71 | HRH2 (0.53) | MAPTNPC1RAB9AGFERATP4A | |
| SCHEMBL10776417 | 0.71 | SLC22A2 (0.50) | MAPTNPC1RAB9AGFERATP4A | |
| SCHEMBL8708729 | 0.71 | CYP1A2 (0.49) | MAPTNPC1RAB9AGFERATP4A | |
| SCHEMBL7143536 | 0.70 | RAB9A (0.60) | MAPTNPC1RAB9AGFERATP4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220125732-A1 | IBUPROFEN AND FAMOTIDINE TABLET | APPCO PHARMA LLC (US) | 2022-04-28 | — | — | US | disclosed |
| EP-3728211-A1 | BIGUANIDE DERIVATIVES AND THEIR REARRANGEMENT PRODUCTS FOR USE IN THE TREATMENT OF CANCER | Centre National de la Recherche Scientifique (FR) | 2020-10-28 | — | — | EP | disclosed |
| EP-0920314-B1 | NON-PEPTIDE G-CSF MIMETICS | SMITHKLINE BEECHAM CORP (US) | 2003-08-27 | — | — | EP | disclosed |
| EP-0920314-A4 | NON-PEPTIDE G-CSF MIMETICS | SMITHKLINE BEECHAM CORP (US) | 2001-08-16 | — | — | EP | disclosed |
| US-5981551-A | GRANULOCYTE COLONY-STIMULATING FACTOR MIMETICS; TREATMENT OF NEUTROPENIA | SMITHKLINE BEECHAM CORPORATION (US) | 1999-11-09 | — | — | US | disclosed |
| EP-0920314-A1 | NON-PEPTIDE G-CSF MIMETICS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-06-09 | — | — | EP | disclosed |
| WO-1997044033-A1 | NON-PEPTIDE G-CSF MIMETICS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220125732-A1 | IBUPROFEN AND FAMOTIDINE TABLET | KIT, PTGER4, GSDMD | MAPT 1727/4885NPC1 3085/4885RAB9A 3330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.